Company intelligence / Profile preview
Aspera Biomedicines, Inc.
La Jolla, California, United Statesasperabiomedicines.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aspera Biomedicines is developing Rebecsinib, a selective splicing modulator that inhibits both ADAR1-mediated immune silencing and pro-survival MCL1-L expression. The drug is currently undergoing IND enabling studies.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of California San Diego
Beyond the preview
Go deeper on Aspera Biomedicines, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspera Biomedicines, Inc..